Showing results (131-140 of 174) with videos related to
Sort By:
Pageof 18
Diagnostics (Basel, Switzerland)|August 28, 2025
Predictive Power of Baseline [<sup>18</sup>F]FDG PET/CT for Adverse Events in DLBCL Patients Undergoing CAR-T Cell TherapyHelena A Peters, Emil Novruzov, Ben-Niklas Bärmann, et al.Haematologica|May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialTheo de Witte, Anne Hagemeijer, Stefan Suciu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2014
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study GroupThomas Schroeder, Elena Rachlis, Gesine Bug, et al.Blood|April 21, 2012
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cellsIngmar Bruns, Ron-Patrick Cadeddu, Ines Brueckmann, et al.Haematologica|March 5, 2026
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenibRadwan Massoud, Sarah Flossdorf, Franziska Hanke, et al.Blood Advances|March 23, 2021
A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantationNico Gagelmann, Anita Badbaran, Dietrich W Beelen, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2019
Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell TransplantationRobert Zeiser, Dietrich W Beelen, Wolfgang Bethge, et al.Bone Marrow Transplantation|April 25, 2024
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)Christian Niederwieser, Simona Iacobelli, Georg-Nikolaus Franke, et al.Transplantation and Cellular Therapy|August 28, 2022
Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic LeukemiaDietrich W Beelen, Renate Arnold, Matthias Stelljes, et al.Pageof 18